Sarah Bhagat has been pivotal to managing numerous investments and has an expanding biotech investing track record, she has made significant contributions of which six have generated realized or unrealized returns. She focuses on biopharmaceutical investments, particularly in gene therapy and orphan diseases with investments in Akouos (AKUS), Atsena, Inozyme (INZY), and Promedior, acquired by Roche for up to $1.4B. Sarah additionally played a central role in Sofinnova’s investments in Apellis (APLS), Pionyr, and YmAbs (YMAB). Sarah is currently the chairwoman of Atsena and is a member of the board of directors for Aeovian and Inozyme (INZY) and a Board Observer for Neurana and NorthSea. Most recently Sarah was recognized by Biocom in 2020 as one of ten life sciences trailblazers under 40.
Prior to joining Sofinnova in 2017, Sarah was a Venture Fellow for Canaan Partners. Sarah was also a postdoctoral fellow in neuroscience at Stanford University. As a graduate student at Yale, Sarah worked with Dr. Stephen Strittmatter, her thesis advisor and co-founder of Axerion Therapeutics, to identify novel targets and develop therapeutics for CNS injury and psychiatric disorders. Prior to Yale, Sarah worked as a research assistant for The Rockefeller University. Before her time at Rockefeller, Sarah was a Clinical Research Coordinator at Massachusetts General Hospital in the Bipolar Clinic and Research Program.
Sarah received her Ph.D. in Neuroscience from Yale University, where she was a National Science Foundation Graduate Research Fellow. Sarah is also an alumna of Stanford’s Graduate School of Business Ignite Entrepreneurship and Innovation Program. Sarah is on the board of Stanford’s Neuroscience Translate Oversight Committee.